Deep Genomics lands $16 mln in follow-on round led by Khosla

Deep Genomics, a Toronto genetic medicine startup, has raised about $16 million (US$13 million) in follow-on financing. U.S. venture capital firm Khosla Ventures led the round and was joined by True Ventures, which led the company's $5 million seed financing in 2015. Spun out of the University of Toronto in 2014, Deep Genomics is building a biologically accurate, data- and artificial intelligence-driven technology platform that supports geneticists, molecular biologists and chemists in the development of therapies. It will use its platform to unlock new classes of anti-sense oligonucleotide therapies and advance them for clinical evaluation. Deep Genomics is led by CEO Brendan Frey.

ManagersCanadaNorth AmericaHealthcareBriefs